Dr. Richard G. Moore
Claim this profileUniversity of Rochester
Studies Gastroesophageal Junction Adenocarcinoma
Studies Endometrioid Adenocarcinoma
13 reported clinical trials
28 drugs studied
Area of expertise
1Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
Stage II
2Endometrioid Adenocarcinoma
Stage IV
Stage I
Stage III
Affiliated Hospitals
Clinical Trials Richard G. Moore is currently running
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
More about Richard G. Moore
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Richard G. Moore has experience with
- Carboplatin
- External Beam Radiation Therapy
- Pembrolizumab
- Cisplatin
- Laboratory Biomarker Analysis
- Paclitaxel
Breakdown of trials Richard G. Moore has run
Gastroesophageal Junction Adenocarcinoma
Endometrioid Adenocarcinoma
Endometrial Cancer
Endometrial Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard G. Moore specialize in?
Richard G. Moore focuses on Gastroesophageal Junction Adenocarcinoma and Endometrioid Adenocarcinoma. In particular, much of their work with Gastroesophageal Junction Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Richard G. Moore currently recruiting for clinical trials?
Yes, Richard G. Moore is currently recruiting for 7 clinical trials in Rochester New York. If you're interested in participating, you should apply.
Are there any treatments that Richard G. Moore has studied deeply?
Yes, Richard G. Moore has studied treatments such as Carboplatin, External Beam Radiation Therapy, Pembrolizumab.
What is the best way to schedule an appointment with Richard G. Moore?
Apply for one of the trials that Richard G. Moore is conducting.
What is the office address of Richard G. Moore?
The office of Richard G. Moore is located at: University of Rochester, Rochester, New York 14642 United States. This is the address for their practice at the University of Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.